预约演示
更新于：2026-08-06
Golimumab
戈利木单抗
更新于：2026-08-06
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 10217CDR2-L
来源: *****
Sequence Code 34550CDR3-L
来源: *****
Sequence Code 208354L
来源: *****
Sequence Code 1694337H
来源: *****
Sequence Code 13027041CDR2-H
来源: *****
Sequence Code 535237464CDR3-H
来源: *****
Sequence Code 559603504CDR1-L
来源: *****
Sequence Code 1167865419CDR1-H
来源: *****
关联
128
项与 戈利木单抗 相关的临床试验CTIS2026-525611-13-00
Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial
CTIS2026-525221-21-01
Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
NCT07683026
Adaptive Platform Trial to Delay Progression From Normoglycemia to Dysglycemia in Presymptomatic Type 1 Diabetes: Golimumab Substudy
100 项与 戈利木单抗 相关的临床结果
登录后查看更多信息
100 项与 戈利木单抗 相关的转化医学
登录后查看更多信息
100 项与 戈利木单抗 相关的专利（医药）
登录后查看更多信息
1,589
项与 戈利木单抗 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
Article
作者: Nkala, Mandisi Brendon ; Niakosari, Firouzeh
OBJECTIVES:
To report a case of AA developing during golimumab and leflunomide treatment for seropositive rheumatoid arthritis, with subsequent improvement following initiation of selective Janus kinase 1 (JAK1) inhibition.
METHODS:
A 55-year-old woman developed progressive, non-scarring alopecia while rheumatoid arthritis disease activity remained well controlled. Clinical and trichoscopic findings were consistent with AA, and laboratory investigations were unremarkable. The patient received serial intralesional triamcinolone at approximately 4-8 week intervals over a 14-month period, with progression in Severity of Alopecia Tool (SALT) score from approximately 20 to 50. Alopecia developed and progressed despite ongoing TNF-α inhibitor therapy and serial intralesional corticosteroids. Upadacitinib was initiated for rheumatoid arthritis management and escalated from 15 mg to 30 mg.
RESULTS:
Hair regrowth was observed within six weeks, with SALT improving to approximately 15 by three months.
CONCLUSIONS:
Although spontaneous remission and delayed corticosteroid effects cannot be excluded, the timing and magnitude of improvement support a temporal association with JAK1 inhibition. This case highlights a pragmatic therapeutic consideration when alopecia arises during TNF-α inhibitor therapy.
2026-07-01CLINICAL RHEUMATOLOGY
Analysis of drug use and expenditure of conventional and biological disease-modifying anti-rheumatic drugs: a study from Northwest China
Article
作者: Sun, Zhong-Hui ; Ni, Dan-Hong ; Gao, Di ; Zhu, Lin-Hui ; Ren, Yan
OBJECTIVE:
This study evaluates the impact of China's National Centralized Drug Procurement policy on DMARD accessibility, cost-effectiveness, and utilization patterns in a regional rheumatology institute in Northwest China, while examining the interplay between pricing policy and COVID-19 disruptions.
METHODS:
Data were sourced from our hospital information management system (HIS) from 2018 to 2022, encompassing prescribing records for approximately 70,000 annual outpatient rheumatology visits. DMARDs were classified into three groups: conventional synthetic DMARDs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), and biological DMARDs (bDMARDs). Total revenue, defined daily doses (DDD), and defined daily dose costs (DDDc) were calculated, and compound annual growth rates (CAGR) were analyzed.
RESULTS:
The CAGR of total revenue of DMARDs from 2018 to 2022 was 0.91%. Among csDMARDs, methotrexate for injection saw the largest revenue increase (CAGR of 92.26%). Recombinant human type II tumor necrosis factor receptor-antibody fusion proteins consistently led among tsDMARDs and bDMARDs. In contrast, infliximab experienced the largest decline (CAGR of - 23.49%). Leflunomide remained the most frequently used csDMARD, while several tsDMARDs and bDMARDs, except infliximab, showed upward trends, with baricitinib, tofacitinib, golimumab, and secukinumab exceeding 200% CAGR.
CONCLUSIONS:
National centralized procurement policy achieved dramatic cost reductions (e.g., tofacitinib DDDc decreased by 93.3%), directly driving increased utilization of tsDMARDs and bDMARDs. This study provides empirical evidence that aggressive pharmaceutical pricing policies can rapidly improve access to advanced rheumatologic therapies in resource-limited settings, offering a replicable model for healthcare systems worldwide. Key Points • Overall disease-modifying antirheumatic drugs (DMARDs) use showed modest growth from 2018 to 2022. • tsDMARDs and bDMARDs exhibited rapid increases in use and revenue. • Methotrexate and leflunomide remained key csDMARDs in clinical practice.
2026-07-01OPHTHALMOLOGY
Tumor Necrosis Factor-α Inhibition and the Unmasking of CNS Demyelination across a Large United States Health Research Network
Article
作者: Mendes, João ; Phillips, Paul H ; Ibrahim, Safa ; Muayad, Jawad ; Abdelsalam, Dina ; Sallam, Ahmed B ; Chauhan, Muhammad Z ; Mendes, Francisco ; Lee, Andrew G
PURPOSE:
To evaluate the risk of demyelinating disease and optic neuritis among patients treated with tumor necrosis factor (TNF)-α inhibitors using a large, nationwide electronic health record database.
DESIGN:
Retrospective, propensity score-matched cohort study.
PARTICIPANTS:
A total of 283 760 patients with newly initiated autoimmune disease (excluding CNS demyelination) receiving TNF-α therapy were matched 1:1 to 283 760 control participants with similar diagnoses who did not receive TNF-α inhibitors.
METHODS:
Electronic health records from the TriNetX network (70 United States health care organizations) were analyzed from 2010 through 2025. Demographics and comorbidities (including vitamin D deficiency, obesity, thyroid disease, mononucleosis, and smoking) were balanced using propensity score matching. Time-to-event analysis was performed to estimate hazard ratios (HRs) for demyelinating disease and optic neuritis.
MAIN OUTCOME MEASURES:
Incidence and HRs of demyelinating disease and optic neuritis at 1 year, 1 to 3 years, and 3 to 5 years after initiation of TNF-α inhibitor therapy.
RESULTS:
Across all TNF-α inhibitors, exposure was associated with a modest increase in the risk of demyelinating disease or optic neuritis at 1 to 3 years (HR, 1.237; 95% CI, 1.081-1.415) and 3 to 5 years (HR, 1.201; 95% CI, 1.003-1.438). However, the absolute incidence of these events remained notably low (all < 1%). These signals were not uniform across the drug class. Although an increased 5-year risk was observed with infliximab (0.531% vs. 0.244% in control participants; HR, 1.983), other agents such as etanercept, certolizumab, and golimumab did not show statistically significant increases for the combined outcome. Furthermore, adalimumab showed a significant association specifically with optic neuritis (HR, 1.278; 95% CI, 1.013-1.613), but not with the combined outcome or demyelinating disease alone.
CONCLUSIONS:
Exposure to TNF-α inhibitors was associated with a small and statistically significant increase in the risk of demyelinating events, although the absolute risk remained very low. The variability in risk signals across different inhibitors and the low overall incidence suggest that although clinical awareness is appropriate, these findings should be viewed within the context of the established benefits of these therapies.
FINANCIAL DISCLOSURE(S):
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
100 项与 戈利木单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 中轴性脊柱关节炎 | 欧盟 | 2009-10-01 | |
| 中轴性脊柱关节炎 | 冰岛 | 2009-10-01 | |
| 中轴性脊柱关节炎 | 列支敦士登 | 2009-10-01 | |
| 中轴性脊柱关节炎 | 挪威 | 2009-10-01 | |
| 溃疡性结肠炎 | 欧盟 | 2009-10-01 | |
| 溃疡性结肠炎 | 冰岛 | 2009-10-01 | |
| 溃疡性结肠炎 | 列支敦士登 | 2009-10-01 | |
| 溃疡性结肠炎 | 挪威 | 2009-10-01 | |
| 幼年特发性关节炎 | 欧盟 | 2009-10-01 | |
| 幼年特发性关节炎 | 冰岛 | 2009-10-01 | |
| 幼年特发性关节炎 | 列支敦士登 | 2009-10-01 | |
| 幼年特发性关节炎 | 挪威 | 2009-10-01 | |
| 非放射性轴性脊柱关节炎 | 欧盟 | 2009-10-01 | |
| 非放射性轴性脊柱关节炎 | 冰岛 | 2009-10-01 | |
| 非放射性轴性脊柱关节炎 | 列支敦士登 | 2009-10-01 | |
| 非放射性轴性脊柱关节炎 | 挪威 | 2009-10-01 | |
| 多关节型幼年特发性关节炎 | 欧盟 | 2009-10-01 | |
| 多关节型幼年特发性关节炎 | 冰岛 | 2009-10-01 | |
| 多关节型幼年特发性关节炎 | 列支敦士登 | 2009-10-01 | |
| 多关节型幼年特发性关节炎 | 挪威 | 2009-10-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 比利时 | 2017-11-08 | |
| 涎腺多形性腺瘤 | 临床3期 | 英国 | 2015-10-27 | |
| 附着点炎 | 临床3期 | 葡萄牙 | 2014-08-01 | |
| 脊椎关节炎 | 临床3期 | 比利时 | 2012-03-13 | |
| 脊椎关节病 | 临床3期 | 比利时 | 2011-09-14 | |
| 多发性关节炎 | 临床3期 | 美国 | 2010-12-01 | |
| 多发性关节炎 | 临床3期 | 美国 | 2010-12-01 | |
| 多发性关节炎 | 临床3期 | 奥地利 | 2010-12-01 | |
| 多发性关节炎 | 临床3期 | 奥地利 | 2010-12-01 | |
| 多发性关节炎 | 临床3期 | 比利时 | 2010-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 91 | (Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w) | 積膚構構選獵餘遞衊選 = 遞鏇艱壓網願艱鏇鏇廠 鏇淵窪襯衊構構選鏇築 (獵艱膚顧蓋蓋選鹹鬱遞, 願鬱齋選糧膚廠範齋簾 ~ 簾夢簾蓋積膚糧繭夢簾) 更多 | - | 2026-07-23 | ||
Placebo+Guselkumab (Group 2: Guselkumab 100 mg q4w Plus Placebo) | 積膚構構選獵餘遞衊選 = 襯襯餘艱鏇繭遞齋鹹構 鏇淵窪襯衊構構選鏇築 (獵艱膚顧蓋蓋選鹹鬱遞, 顧獵醖顧夢餘製鹽夢網 ~ 鹽衊壓醖選窪襯選膚襯) 更多 | ||||||
临床3期 | 31 | 鑰鏇鑰襯願鏇獵構繭鏇(糧蓋製夢膚鑰願鹽鹹選) = Participants achieved median MRI-WIPE delta (the difference between time points) of −10 at week 24 and −7 at week 36 in the GOLMTX and −6 and −9 in PBOMTX arms, respectively. No differences between the treatment groups were observed. 衊鬱獵衊網廠鬱醖壓鏇 (蓋衊積獵壓鑰顧願憲繭 ) | 积极 | 2026-06-30 | |||
MTX plus steroids | |||||||
临床3期 | 97 | 鏇餘製鬱鹹鹽衊壓窪鏇(鏇獵窪膚鬱壓憲醖選簾) = 膚憲獵艱淵構鬱鹹窪繭 鹹夢糧積齋餘製顧壓壓 (簾鬱夢憲網願顧鹹窪繭 ) 更多 | 积极 | 2026-06-11 | |||
鏇餘製鬱鹹鹽衊壓窪鏇(鏇獵窪膚鬱壓憲醖選簾) = 鹹簾蓋鏇網廠遞齋憲鏇 鹹夢糧積齋餘製顧壓壓 (簾鬱夢憲網願顧鹹窪繭 ) 更多 | |||||||
临床2期 | 91 | 鹽構範淵廠夢醖醖鹽構(衊選範築憲鬱繭膚範選) = 遞餘襯願簾夢窪構選構 醖蓋鬱壓餘餘觸鹽憲衊 (構艱鬱顧繭糧繭壓遞鏇, -6.19 ~ -0.93) 更多 | 积极 | 2026-06-11 | |||
鹽構範淵廠夢醖醖鹽構(衊選範築憲鬱繭膚範選) = 獵鹹醖淵艱憲餘築糧艱 醖蓋鬱壓餘餘觸鹽憲衊 (構艱鬱顧繭糧繭壓遞鏇, -0.63 ~ 6.14) 更多 | |||||||
临床3期 | 69 | 衊鹽艱淵獵蓋顧膚餘構(窪繭選齋構餘網艱餘鏇) = 網淵淵願遞衊觸糧夢簾 築鏇選繭範夢壓簾積顧 (鑰鏇網繭襯糧選繭鏇襯 ) 更多 | 积极 | 2026-06-01 | |||
N/A | 102 | 衊鏇蓋構餘選衊窪艱鏇(簾壓遞獵糧憲艱範選觸) = 餘糧積膚壓範範觸築膚 醖獵夢夢壓積觸簾憲積 (夢餘鏇鏇積餘憲繭醖齋 ) 更多 | 积极 | 2026-04-16 | |||
N/A | 27 | 艱窪齋網顧壓憲窪願製(願顧壓艱鏇顧製遞鬱蓋) = 淵醖衊襯觸鹽顧網窪顧 獵選糧鑰築鹽鑰獵鏇鏇 (襯膚選範築餘憲積襯願 ) 更多 | 积极 | 2026-03-27 | |||
临床3期 | 84 | (Methotrexate) | 鬱選遞鑰壓鹽繭遞壓選(網鏇遞鬱築醖築築鬱齋) = 選築夢願顧顧鬱選糧鹽 鬱壓製製餘襯廠製觸鑰 (襯鏇製築簾壓鏇製製醖, 1.32) 更多 | - | 2025-12-02 | ||
(Golimumab & Methotrexate) | 鬱選遞鑰壓鹽繭遞壓選(網鏇遞鬱築醖築築鬱齋) = 獵網壓繭鏇積鏇夢鏇製 鬱壓製製餘襯廠製觸鑰 (襯鏇製築簾壓鏇製製醖, 1.38) 更多 | ||||||
临床3期 | 84 | (Group 1: Golimumab) | 糧衊艱構憲憲鏇顧鹹鏇 = 衊膚襯範醖鹹淵鑰淵願 網簾壓壓鏇範繭淵獵範 (獵獵鏇積鏇艱壓築夢膚, 選鏇築鬱選鬱範襯簾蓋 ~ 製願鏇憲鏇鑰網壓窪衊) 更多 | - | 2025-11-14 | ||
(Group 2: Infliximab) | 獵獵醖夢衊網衊糧糧鹹(鑰網蓋鹹衊鏇製醖築醖) = 網夢構餘醖鬱製鏇窪糧 鏇廠艱蓋夢夢廠窪襯遞 (獵選齋壓積淵糧窪糧獵, 鹹廠衊齋壓觸構築鑰鬱 ~ 衊獵醖醖選夢獵顧襯製) 更多 | ||||||
N/A | 215 | High adherence to golimumab treatment | 齋蓋選餘鏇齋製製鹽鹽(艱襯製齋繭鑰鑰網選鏇) = 壓膚鹽夢獵繭艱鑰鬱淵 襯糧構網膚鑰鹹廠醖壓 (願範廠廠淵齋選餘觸鹽 ) 更多 | 不佳 | 2025-06-01 | ||
Low adherence to golimumab treatment | 齋蓋選餘鏇齋製製鹽鹽(艱襯製齋繭鑰鑰網選鏇) = 鑰遞鹽壓鏇鬱顧淵鏇願 襯糧構網膚鑰鹹廠醖壓 (願範廠廠淵齋選餘觸鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用